These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34869384)

  • 1. The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy.
    Wu S; Sun R; Tan B; Chen B; Zhou W; Gao DS; Zhong J; Huang H; Jiang J; Lu B
    Front Cell Dev Biol; 2021; 9():779865. PubMed ID: 34869384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment.
    Wu S; Huang H; Sun R; Gao DS; Ye F; Huang J; Li E; Ni A; Lu KG; Chen K; Jiang J; Morel PA; Zhong Z; Lu B
    Cancer Res Commun; 2023 Aug; 3(8):1460-1472. PubMed ID: 37546701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment.
    Yang M; Du W; Yi L; Wu S; He C; Zhai W; Yue C; Sun R; Menk AV; Delgoffe GM; Jiang J; Lu B
    Oncoimmunology; 2020; 9(1):1708064. PubMed ID: 32076578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
    Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.
    Deng S; Sun Z; Qiao J; Liang Y; Liu L; Dong C; Shen A; Wang Y; Tang H; Fu YX; Peng H
    JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune cell contexture in the tumor microenvironment].
    Fujii SI
    Rinsho Ketsueki; 2020; 61(9):1424-1432. PubMed ID: 33162545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
    Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
    ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
    Huang RY; Francois A; McGray AR; Miliotto A; Odunsi K
    Oncoimmunology; 2017; 6(1):e1249561. PubMed ID: 28197366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumors establish resistance to immunotherapy by regulating T
    Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
    Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R
    Clin Med Insights Oncol; 2021; 15():11795549211035540. PubMed ID: 34408525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
    Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
    Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.